Godavari Biorefineries Ltd returned to profitability in FY26, recording a net profit of ₹3.5 crore against a net loss of ₹23.4 crore in the previous fiscal year. Revenue from operations for the year stood at ₹1,987.9 crore, up 6.3% from ₹1,870.3 crore in FY25. The turnaround was driven by a resilient performance across its integrated bio-refinery segments, despite a challenging operating environment marked by elevated cane and feedstock costs in the fourth quarter. The audited standalone and consolidated financial results were approved by the board on May 22, 2026, and published in newspapers on May 24, 2026, pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For the quarter ended March 31, 2026, the company posted a net profit of ₹52.9 crore, compared to ₹71.9 crore in the same quarter of the previous year. Total income for Q4 FY26 was ₹570 crore, while EBITDA stood at ₹92.1 crore, with margins contracting to 16.2% from 20.7% a year ago.

Financial Performance

The company's total income for FY26 increased to ₹2,000.2 crore from ₹1,886.9 crore in FY25. Profit before exceptional items and tax for the year was ₹35.7 crore, a significant improvement from the loss of ₹1.5 crore reported in the previous year. The following table summarises the key annual and quarterly financial metrics:

Operational Highlights

During the 2025-26 crushing season, the company achieved its highest-ever cane crushing of 2.5 Mn tonnes. The Integrated Sugar, Cogen & Ethanol segment reported an EBITDA of ₹83.9 crore for Q4 FY26, while the Bio Based Chemicals segment recorded an EBITDA of ₹9.5 crore. The consumer business, Jivana, revenues crossed ₹129 crore in FY26 compared to ₹108 crore in FY25.

Segment-wise revenue for FY26 showed growth across key verticals. The Bio-Based Chemicals segment revenue grew 6.6% to ₹578 crore, while the Integrated Sugar, Co-gen & Ethanol segment revenue increased 5.8% to ₹1,383.2 crore. The company also strengthened its innovation portfolio with the grant of a Japanese patent related to antiviral therapeutics during the quarter.

Pursuant to Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the earnings conference call for Q4 and FY26 has been uploaded on the company website.

Godavari Biorefineries Limited has published its postal ballot notice in newspapers on May 26, 2026, seeking shareholder approval for the re-appointment of two key directors. The company is proposing to re-appoint Mr Nitin Mehta as an Independent Director for a second term of five years and Dr Sangeeta Srivastava as a Whole Time Director, designated as an Executive Director, for a period of three years. The resolutions require approval through special resolutions via remote e-voting.

Voting Schedule and Process

The remote e-voting period begins on May 29, 2026, at 9:00 a.m. IST and concludes on June 28, 2026, at 5:00 p.m. IST. The company has engaged National Securities Depository Limited (NSDL) to facilitate the electronic voting process. Shareholders whose names appear in the Register of Members or List of Beneficial Owners as on the Cut-Off Date of May 15, 2026, are eligible to vote. The results of the postal ballot will be announced on or before June 30, 2026.

Director Re-appointments

The Board has recommended the re-appointment of Mr Nitin Mehta (DIN: 09174633) as an Independent Director. His current term ends on June 30, 2026, and the proposed re-appointment is for a term commencing July 1, 2026, to June 30, 2031. The company stated that Mr Mehta meets the criteria for independence and has submitted the necessary declarations and consents.

Additionally, the company seeks approval for the re-appointment of Dr Sangeeta Srivastava (DIN: 00480462) as a Whole Time Director, designated as an Executive Director. Her re-appointment is proposed for a term of three years effective from August 1, 2026. The remuneration package includes a basic salary of ₹ 492,066 per month and a special allowance of ₹ 2,39,696 per month, among other perquisites.

Financial Performance

The explanatory statement accompanying the notice detailed the company's financial performance for the fiscal years 2025-2026 and 2024-2025. The company reported a turnaround in profitability for the year 2025-2026.

The document noted that the financial year 2025-2026 faced a challenging operational environment due to elevated cane and feedstock costs. However, the company expects improved capacity utilizations in the chemical sector to contribute to gains from the current quarter onwards.